Cumulative evidence indicates that some miRNAs act as either oncogenes or tumor suppressors in the tumorigenesis of CRC and possess the tumor marker potential for diagnostic, therapeutic, prognostic exploration [ 3- 9].
They can be distinguished from each other based on their size, growth in cell culture, expressed genes, cell surface markers, and potential for differentiation.
However, none of the markers show potential for ILC imaging.
These markers have potential for mapping and as anchor points for carrot map merging.
Notably, EZH2 may serve as a novel marker with potential for clinical oncology.
I do not think it is in the best interests of the Association to sponsor the markers given the potential for controversy.
Just like fingerprints and faces, voice prints are biometric markers with tremendous potential for forensic, military, and commercial applications[1].
Metabolomic markers have the potential for translation into diagnostic, predictive, or screening tests in perinatal research.
Amongst these markers exists the potential for emergent prognostic, predictive and therapeutic targeting.
Consequently, EST-SSRs arise as molecular markers with great potential for comparative studies among species.
